US 11,752,144 B1
Compounds and combinations thereof for treating neurological and psychiatric conditions
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Feb. 23, 2023, as Appl. No. 18/173,291.
Claims priority of provisional application 63/359,143, filed on Jul. 7, 2022.
Claims priority of provisional application 63/370,592, filed on Aug. 5, 2022.
Claims priority of provisional application 63/396,182, filed on Aug. 8, 2022.
Claims priority of provisional application 63/373,040, filed on Aug. 19, 2022.
Claims priority of provisional application 63/401,541, filed on Aug. 26, 2022.
Int. Cl. A61K 31/485 (2006.01); A61K 31/137 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 31/137 (2013.01)] 14 Claims
 
1. A method of using a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist to treat major depressive disorder, comprising administering, no more than twice daily, a combination of 105 mg of bupropion hydrochloride and 45 mg of dextromethorphan hydrobromide to a human patient who is experiencing major depressive disorder, wherein the human patient has a history of drug abuse, and wherein the human patient does not experience dissociation.